Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1 5Phase 3 3Phase 1/2 2

Status

Completed 4Active not recruiting 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5Thoracic 3Sarcoma 1Other solid neoplasm 1Gynecologic 1Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 50Neoplasms 22Pancreatic Neoplasms 21Neoplasm Metastasis 12Lung Neoplasms 12Brain Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Head and Neck Neoplasms 7Breast Neoplasms 7Gliosarcoma 6Glioblastoma 6Salivary Gland Neoplasms 5Rectal Neoplasms 5Glioma 5Colorectal Neoplasms 5Colonic Neoplasms 5Astrocytoma 5Unspecified Adult Solid Tumor, Protocol Specific 4Solid Tumors 4Esophageal Neoplasms 4Tongue Neoplasms 3Prostatic Neoplasms 3Oligodendroglioma 3Lymphoma 3Gallbladder Neoplasms 3Central Nervous System Neoplasms 3Carcinoma, Hepatocellular 3Bile Duct Neoplasms 3Advanced Cancers 3Advanced Cancer 3

Interventions

Fluorouracil 71pembrolizumab 62Bevacizumab 60Oxaliplatin 59Cetuximab 59Leucovorin 56Irinotecan 55Capecitabine 31Nivolumab 23Gemcitabine 18Cisplatin 18IFL protocol 17Folfox protocol 17Cyclophosphamide 16Carboplatin 15atezolizumab 14Specimen Handling 14Paclitaxel 14Magnetic Resonance Spectroscopy 14Biopsy 14trifluridine tipiracil drug combination 12Pemetrexed 10spartalizumab 9regorafenib 9fludarabine 9Panitumumab 9130-nm albumin-bound paclitaxel 9trametinib 8durvalumab 8dehydroftorafur 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1 × Colorectal Neoplasms × Erlotinib Hydrochloride × Clear all
NCT04449874 2026-06-02

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

Genentech, Inc.

Phase 1 Active not recruiting
498 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Colorectal Neoplasms

NCT00739453 2024-11-20

A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)

Astellas Pharma Inc

Phase 1 Completed
95 enrolled
GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT00118261 2012-09-03

Erlotinib, Modified FOLFOX6, and Bevacizumab as First-Line Therapy Metastatic Colorectal Cancer

Case Comprehensive Cancer Center

Phase 1 Completed
17 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00603356 2011-09-27

Phase I Study of OSI-930 and Erlotinib in Cancer Tumors

Astellas Pharma Inc

Phase 1 Completed
60 enrolled
GastrointestinalGynecologicOther solid neoplasmSarcomaThoracic

Mesothelioma, Neoplasms, Ovarian Neoplasms, Sarcoma, Colorectal Neoplasms

NCT00047762 2005-06-24

Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer

Genentech, Inc.

Phase 1 Completed
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡